Artrite Idiopática Juvenil: Atualização

Amanda D. Maliki, Flavio R. Sztajnbok

Resumo


A artrite idiopática juvenil (AIJ) atualmente não é reconhecida como uma única doença, e sim como um termo que engloba todas as formas de artrite crônica que se iniciam antes dos 16 anos de idade, com duração maior que seis semanas e de causa desconhecida. Em 1997, a Liga Internacional de Associações para a Reumatologia (ILAR, do inglês International League of Associations for Rheumatology) propôs uma nova forma de classificação, aceita mundialmente, segundo a qual a AIJ se divide em sete principais subtipos cujo tratamento e prognóstico variam de acordo com os seus diferentes fenótipos. O objetivo deste artigo é abordar os conceitos mais atuais acerca do diagnóstico e terapêutica da doença.Descritores: Artrite idiopática juvenil; Artrite reumatoide juvenil; Diagnóstico; Tratamento; Criança.

Referências


Petty RE, Southwood TR, Manners P, et al. International League of Associations for Rheumatology Classification of Juvenile Idiopathic Arthritis: Second Revision, Edmonton. 2001. J Rheumatol. 2004;31:2.

Ravelli A, Martini A. Juvenile Idiopathic Arthritis. Lancet. 2007;369:767–78. http://doi.org/10.1016/S0140-6736(07)60363-8

Beukelman T, Patkar NM, Saag KG, et al. 2011 American college of rheumatology recommendations for the treatment of juvenile idiopathic arthritis; initiation and safety monitoring of therapeuthic agents for the treatment of arthritis and systemic features. Arthritis Care Res. 2011;63(4):465-482. http://doi.org/10.1002/ACR.20460

Duurland CL, Wedderburn LR. Current developments in the use of biomarkers for juvenile idiopathic arthritis. Curr Rheumatol Rep. 2014:16:406. http://doi.org/10.1007/s11926-013-0406-3

Oen KG, Cheang M. Epidemiology of chronic arthritis in childhood.Semin. Arthritis Rheu. 1996;26:575-591.

Andersson B. Juvenile arthritis—who gets it, where and when? A review of current data on incidence and prevalence.Clin. Exp. Rheumatol. 1999;17:367-374.

Bernston L, Anderson GB, et al. Incidence of juvenile idiopathic arthritis in the Nordic countries: a population-based study with special reference to the validity of the ILAR and EULAR criteria. J Rheumatol. 2003;30:2275-82.

Beukelman T. Treatment advances in systemic juvenile idiopathic arthritis. F1000Prime Reports 2014: 6:21. http://doi.org/10.12703/P6-21

Ravelli A, Magni-Manzoni S, Pistorio A, et al. Preliminary diagnostic guidelines for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. J Pediatr. 2005;146:598–604. http://doi.org/10.1016/j.jpeds.2004.12.016

Sawhney S, Woo P, Murray KJ. Macrophage activation syndrome: a potentially fatal complication of rheumatic disorders. Arch Dis Child. 2001; 85:421–6.

Janka GE. Familial and acquired hemophagocytic lymphohistiocytosis. Eur J Pediatr. 2007;166:95–109. http://doi.org/10.1007/s00431-006-0258-1

Masters S, Simon A, Aksentijevich I, et al. Horror autoinflammaticus: the molecular pathophysiology of autoinflammatory disease. Ann Rev Immunol. 2009;27:621–68. http://doi.org/0.1146/annurev.immunol.25.022106.141627

Mellins ED, Macaubas C, Grom AA. Pathogenesis of systemic juvenile idiopathic arthritis: some answers, more questions. Nat Rev Rheumatol; 2011: 416-26. http://doi.org/10.1038/nrrheum.2011.68

Boom V, Anton J, Lahdenne P, et al. Evidence-based diagnosis and treatment of macrophage activation syndrome in systemic juvenile idiopathic arthritis. Pediatr Rheumatol; 2015: 13-55. http://doi.org/10.1186/s12969-015-0055-3

Felici E, Novarini C, Magni-Manzoni S, et al. Course of joint disease in patients with antinuclear antibody-positive juvenile idiopathic arthritis. J Rheumatol 2005; 32: 1805-10.

Petty RE, Smith JR, Rosembaum JT, et al. Arthritis and uveitis in children. A pediatric rheumatology perspective. Am J Ophtalmol. 2003;135:879-84.

Ostrov BE. What is the significance of dry synovitis? Pediatr Rheumatol online J. 2004;2:114-8.

AL-Mayouf SM, AL-Mehaidib AI, Alkaff MA. The significance of elevated serologic markers of celiac disease in children with juvenile rheumatoid arthritis. The Saudi J Gastroenterol. 2003;9(2):75–8.

Celiloglu C, Karabiber H, Selimoglu MA. Atypical presentations of celiac disease. Turk J Pediatr. 2011;53(3):241–9.

Molberg, Oyvind, McAdam, et al. Role of Tissue Transglutaminase in Celiac Disease. Pediatr. Gastroenterol. Nutr. 2000;30:232–40.

Rodrigo L. Celiac disease. World J Gastroenterol. 2006;12(41):6585–93.

Robazzi TC, Adan LF, Pimentel K, et al. Autoimmune endocrine disorders and coeliac disease in children and adolescents with juvenile idiopathic arthritis and rheumatic fever. Clin Exp Rheumatol 2013; 31: 310-317.

Colebatch-Bourn AN, Edwards CJ, Collado P, et al. EULAR- PReS points to consider for the use of imaging in the diagnosis and management of juvenile idiopathic arthritis in clinical practice. Ann RheumDis2015;(74):1946-1957. http://doi.org/10.1136/ANNRHEUMDIS-2015-207892

Kasapçopur O, Barut K. Treatment in juvenile rheumatoid arthritis and new treatment options. TurkPedArs 2015; 50: 1-10. http://doi.org/10.5152/tpa.2015.2229